跳至主要内容
临床试验/ACTRN12622001266752
ACTRN12622001266752尚未招募未知

Multi-centre Study to evaluate the survivorship of the Medacta GMK SpheriKA Total Knee following primary Total Knee Arthroplasty

Medacta Australia Pty Ltd0 个研究点目标入组 280 人开始时间: 2022年9月26日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
280

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • •Patients undergoing a primary total knee replacement according to the indications for use (On-Label use).
  • •Patients with intact collateral ligaments
  • •Patients ability to use a mobile phone app to answer the questionnaires

排除标准

  • •Patients with inflammatory arthritis.
  • •Patients with a history of total or unicompartmental reconstruction of the affected joint.
  • •Patients that have had a high tibial osteotomy or femoral osteotomy.
  • •Patients with neuromuscular or neurosensory deficiency,
  • •Patients with bad chronic disease
  • •Previous instability of patello-femoral joint/previous surgery for patello-femoral stabilisation
  • •Patients that are immunologically compromised
  • •Patients presenting with emergency procedures
  • •Patients with an intellectual or physical disability preventing them from using the APP.
  • •Patients that do not own a smart phone or device will need to be excluded from the study.

研究者

相似试验